research

A top MS researcher for Biogen Idec answered questions in an exclusive interview with Multiple Sclerosis News Today correspondent Dr. Ana de Barros at a Satellite Symposia entitled “MS developments: transitioning evidence into clinical practice” presented by the company this morning at the 31st Congress of the European Committee for Treatment and…

A new study recently published in the journal Neurology: Neuroimmunology & Neuroinflammation revealed that the drug Cladribine does not increase the risk of cancer in patients with multiple sclerosis (MS) as previously thought. The study was led by researchers at Queen Mary University of London (QMUL)…

A Satellite Symposia entitled “Discovering a new world in MS” supported by Teva Neuroscience was held yesterday, October 8, at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), currently taking place in Barcelona, Spain, October 7 – 10, 2015. Prof. David Brassat…

The 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) is currently being held in Barcelona, from 7 to 10 of October, 2015. As the biggest scientific event focused on Multiple Sclerosis, researchers and clinicians from around the world, with more than 8,000 participants, gather…

New developments in the diagnosis and treatment of multiple sclerosis (MS) are being discussed at this year’s 31st annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The symposium, being held in Barcelona, Spain, will foster discussions about development of individualized therapies for MS patients through a more targeted and efficient…

Genzyme recently announced results from magnetic resonance imaging (MRI) analysis of participants in the Phase III TEMSO clinical trial showing that Aubagio® (teriflunomide) was able to slow the loss of brain volume (or atrophy) versus a placebo over two years in patients with relapsing multiple sclerosis (RMS). Brain volume loss (BVL)…

The world’s largest generic medicines manufacturer, Teva Pharmaceutical, is at the 31st European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress currently ongoing in Barcelona, from October 7-10, 2015. Teva will be presenting the latest findings on its relapsing multiple sclerosis (MS) therapy COPAXONE® (glatiramer acetate injection), and product candidate for…

A number of studies have previously suggested a negative effect of high cholesterol levels on the development of brain lesions in patients with multiple sclerosis (MS), however, little is known about the effect of HDL (high-density lipoprotein) cholesterol, or “good” cholesterol, on MS. A team of scientists from the University…

The 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) begins today, October 7, 2015 at the Centre de Convencions Internacional de Barcelona (CCIB) in Barcelona, Spain. The first day of the Congress will focus heavily on Teaching Courses in several topics related to multiple sclerosis (MS)…

The 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) will start today, 7 October 2015 at the Centre de Convencions Internacional de Barcelona (CCIB) in Barcelona, Spain. The first day of the Congress is heavily focused on Teaching Courses in several topics related to multiple…

Icometrix, a leader in magnetic resonance imaging (MRI) biomarkers for multiple sclerosis (MS), has recently announced a collaboration agreement with Novartis Pharma AG regarding MSmetrix – a measurement tool especially designed to assess brain volume and atrophy, as well as existing, new or enlarging brain lesions in MS patients. Monitoring…

The Patient-Centered Outcomes Research Institute (PCORI) Board of Governors recently approved an $83 million grant to support 26 patient-centered, comparative effectiveness clinical research (CER) studies on a range of diseases and patient groups. Two of these grants, totaling $29.5 million, will fund research into the care of patients infected with hepatitis…

A new study recently published in the journal PLOS ONE revealed that high intensity exercise is safe and offers clinical benefits for patients with multiple sclerosis (MS). The study is entitled “High Intensity Exercise in Multiple Sclerosis: Effects on Muscle Contractile Characteristics and Exercise…

The 31st meeting of the Congress of the European Committee for Treatment and Research in Multiple Sclerosis (#ECTRIMS2015) is being held this week from October 7 to 10 in Barcelona, Spain. The conference was last held in the Catalonian capital in 1992. Multiple Sclerosis News Today…

Kessler Foundation researchers recently reported that the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) is able to predict the performance of normal daily activities. According to the researchers, the BICAMS is a promising tool to predict actual functional performance in participants with multiple sclerosis (MS). MS is a progressive…

Two studies recently published in the journal Science Translational Medicine, revealed a possible new vaccine treatment for JC virus with important implications for multiple sclerosis (MS) treatment. The studies are entitled “JC polyomavirus mutants escape antibody-mediated neutralization” and “Broadly neutralizing human…

In a new study entitled “The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients,” a team of scientists discovered that differences in response to glatiramer acetate therapy among multiple sclerosis (MS) patients is potentially dependent on the presence of reactive brain-specific B…

A study led by researchers from the University of Buffalo recently reported the development of a new method to study brain cell interaction more precisely. The study, published in the journal Nature Communications and entitled “Spatial mapping of juxtacrine axo-glial interactions identifies novel molecules in peripheral…

In a new study entitled “LINGO-1 antibody ameliorates myelin impairment and spatial memory deficits in experimental autoimmune encephalomyelitis mice”, a team of scientists report that the loss of myelin in multiple sclerosis (MS) patients’ brains contributes to their cognitive impairment. They showed that inhibiting protein LINGO-1 can…

A review study recently published in the journal Cochrane Database of Systematic Review (CDSR) focused on the clinical benefit of different therapies available for relapsing-remitting multiple sclerosis (RRMS). The study is entitled “Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis” and was led…

In a recent review published in the European Journal of Neurology, A. P. Lysandropoulos from the University of Brussels and E. Havrdova, from the University of Prague described some ‘hidden’ issues that influence the quality of life (QoL) in patients with multiple sclerosis (MS). In the review,…

A study recently published in the European Journal of Neurology reviewed some of the issues associated with pregnancy in multiple sclerosis (MS) patients. The study is entitled “An overview of pregnancy-related issues in patients with multiple sclerosis” and was developed by researchers at Sapienza…

Results from a recent Brazilian study, published in the journal Arquivos de Neuro-Psiquiatria, revealed that natalizumab is an effective treatment for multiple sclerosis (MS) patients. The study is entitled “Natalizumab treatment in multiple sclerosis: the experience from two Brazilian MS centers“. MS is…

Aphios Corporation, a green biotechnology company based in Massachusetts that uses environmentally sustainable technologies, recently announced it was awarded the Phase II portion of a Fast Track SBIR grant from the National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH) for the production of cannabidiol (CBD) from marijuana.

An international research team recently reported that the web-based MSdialog app is being adopted by both multiple sclerosis (MS) patients and healthcare providers. The study is entitled “Patient and Physician Perspectives on MSdialog, an Electronic PRO Diary in Multiple Sclerosis” and was published in the journal…

A new study recently published in the journal PLOS One revealed that multiple sclerosis (MS) patients have a microbial imbalance (dysbiosis) in their gut microbiota that is most likely linked to the disease pathogenesis. The study is entitled “Dysbiosis in the Gut Microbiota of…

Melatonin, the same hormone that helps people fall asleep by regulating the body’s internal clock, may be helpful in treating multiple sclerosis, according to a study from Raúl Carrea Institute for Neurological Research in Buenos Aires. Neurologists Dr. Mauricio Farez and Dr. Francisco Quintana noticed that when melatonin levels are…

In a newly published study in the PLOS One journal entitled “Reliability of Intra-Retinal Layer Thickness Estimates“, researchers from Germany explored the precision and reliability of a medical imaging technique named optical coherence tomography (OCT) in measurements of thickness of different intra-retinal layers in…

Biogen recently announced an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC), a research-driven pharmaceutical company based in Japan, to exclusively license the company’s experimental product MT-1303. The product is a late stage experimental oral compound developed as a therapy for several autoimmune conditions. MT-1303 is a sphingosine 1-phosphate (S1P)…

A recently published study in the journal Multiple Sclerosis and Related Disorders found notably higher mortality and comorbidity rates among patients suffering from multiple sclerosis (MS) compared to those without the disease. While past studies have reported similar observations, much remains to be understood about MS patients’ risk…